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ABSTRACT 
 The 2nd International Consensus Conference for Breast Cancer in Young Women (BCY2) 
took place in November 2014, in Dublin, Ireland organized by the European School of Oncology 
(ESO). Consensus recommendations for the management of breast cancer in young women 
(BCYW) were updated from BCY1 with incorporation of new evidence to inform the guidelines, 
and areas of research priorities were identified. This manuscript summarizes these international 
consensus recommendations, which are also endorsed by the European Society of Breast Specialists 
(EUSOMA). 
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Introduction 
Breast cancer is the leading cause of cancer and of cancer death amongst women worldwide1. 
BCYW (≤40 years) women is uncommon, with a 0.40-0.45% cumulative risk by that age1. Overall, 
they represent less than 7% of women diagnosed with breast cancer in developed countries 2. 
Despite the relatively low cumulative risk, in high-income countries breast cancer is the leading 
cause of death amongst women under the age of 45 years, following road traffic accidents and self-
injury, making BCYW a significant public health issue3. While the incidence has not increased in 
many countries young women are a growing population and thus the absolute number of women at 
risk has increased. Data on breast cancer epidemiology and clinical-biological behaviour is based 
predominantly on older breast cancer patients resulting in a relative paucity of data in young 
women.  
BCYW is a distressing and far-reaching disease - it strikes the women at the peak of their careers, 
motherhood plans and family life. The treatments they receive may adversely affect their fertility 
and induce premature menopause. Thus they face not only the threat of a potentially fatal illness, 
but they have the added burden, specific to their age-group and stage in life, of unique concerns on 
the long-term disease impact. Most concerning, young women on average experience increased risk 
of both local and systemic recurrence and death after a diagnosis of breast cancer.4 This is largely 
due to their increased risk of biologically aggressive cancer types (i.e., more high grade when ER+, 
increased HER2-positive and triple negative disease) and more advanced stage. 5-9 The biologic, 
medical and psychosocial underpinnings of this disparity in disease outcomes are an area of active 
research, particularly whether or not young age alone will remain an independent prognostic factor 
as we improve our understanding of molecular sub-typing. Consequently, young women often need 
and receive aggressive multimodality treatments (i.e., surgery, radiation, chemotherapy, biological 
therapies and endocrine therapy as appropriate), each of which can cause significant long-term side 
effects and influence quality of life. Additionally, because they have generally not been studied in 
large numbers, young women may not benefit from our increasing ability to better risk stratification 
of breast cancer, and some young women may be at risk of being over-treated based solely on age. 
Young women are also more likely to harbour a genetic predisposition to breast cancer (e.g., a 
BRCA1 or BRCA2 mutation) than older women, especially if the disease is triple negative. This 
hereditary predisposition may impact on their local treatment decisions and considerations for risk-
reducing surgeries, such as contralateral mastectomy and salpingo-oophorectomy10 to actively 
reduce future cancer risks, which may result in  additional psychosocial adjustments.11-13 Research 
has consistently shown that young women with breast cancer are at increased risk of psychological 
distress at diagnosis and in long-term follow-up14, 15 and yet have traditionally had far less 
organized peer- and professional support available to them.  
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In recent years, there have been an increasing number of prospective studies focused on young 
women. However there remains an urgent need for intervention studies to understand and improve 
outcomes in this population.6, 16, 17 
For the purpose of these recommendations, consistent with previous guidelines18, 19, the panel 
decided to define “young women” as women under the age of 40 at breast cancer diagnosis in 
recognition that these women have specific issues (e.g. fertility, genetics and psychosocial 
concerns) that often deserve a different approach compared to older premenopausal patients. The 
application and use of consensus guidelines have previously been demonstrated to have a positive 
impact on breast cancer care20, 21. 
 
Methodology 
 Recommendations from BCY1 formed the basis for the current recommendations19. The 
updated statements from BCY2 were presented, discussed and voted on during the consensus 
session of BCY2. All panel members were instructed to vote on all questions; with members with a 
potential conflict of interest or who did not feel comfortable responding (e.g., due to lack of 
expertise on the topic) instructed to abstain for that particular question. Where there were areas of 
substantial controversy or disagreement, it is noted in the discussion of the recommendations. These 
recommendations were circulated to panel members by email for comments, updating based on 
recent reports, and corrections on content and wording. 
 Table 1 describes the grading system used.22 Statements without grading were considered 
justified standard clinical practice by the panel experts.  
Appendix 1 lists all members of the BCY2 consensus panel and their disclosure of any 
relationships with the pharmaceutical industry that could be perceived as a potential conflict 
of interest. 
 
General Considerations When Caring for Young Women with Breast Cancer (Table 2) 
 The panel reinforced the concept that the complex care of BCYW requires additional 
specialists (e. g. geneticists, fertility and psycho-social experts). Specialized breast clinics allow for 
such a multidisciplinary approach, for women with breast cancer in general23, 24, and specifically 
young patients.25 Thus, the panel agreed that all young patients should be cared for in specialized 
breast clinics that incorporate treatment coordinators. The team should be appropriate for the 
current management of clinical issues, and additional specialists should be available for 
consultation (i.e. fertility service providers, psycho-social health professionals, physiotherapists and 
sexual experts) recognizing that access to such professionals may be limited, particularly in lower 
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resource settings. Keeping this in mind the panel stated that navigators/navigation tools may be of 
great assistance in optimizing patient care. Navigators should ideally be breast nurses but lay-health 
professionals with strong communication skills and sufficient experience may also address complex 
care and mixed cultural settings26. Studies have shown that incorporating navigators in health 
clinics improves patients’ sense of empowerment and increases the uptake of standard therapies26-28. 
Where human resources may be more limited, internet/technology based-tools may be an option to 
assist in patient navigation.  
 Panel members reemphasized that many specific issues in the treatment of young women 
with breast cancer, both in the early and in the advanced settings, still lack definitive proven 
standards. Therefore, well-designed, independent, prospective randomized trials should be a global 
research priority.  
 Extensive data suggest that tumours in younger women tend to be of more aggressive 
phenotypes.5-9, 16 Recent studies suggest potentially unique biology of tumors arising in younger 
patients.7, 29-31 Whether young age alone represents an independent prognostic or predictive factor 
as we improve our understanding of tumor sub-typing remains an area of active research with 
significant clinical implications. At this time the choice of most treatments for young women, both 
in the early and the advanced setting, should be driven by similar factor as for older women, i.e. by 
the biological characteristics of the tumour (i.e. hormone receptors, HER2, proliferation, grade), 
tumour stage, hormonal milieu (i.e. the panel wished to emphasize that chemotherapy or treatment 
induced amenorrhoea is not equivalent to menopause), patient's co-morbidities and personal 
preferences, especially when benefits may be modest or options are equivalent in outcome (e.g, 
mastectomy versus breast conservation).23, 32 The panel reinforced the concept that young age alone 
should not be a reason to prescribe more aggressive therapy. 
 
Diagnosis & Imaging for Staging and follow-up (Table 3) 
 The panel re-discussed ultrasound (US) and magnetic resonance (MRI) as specific 
diagnostic tools in young women and confirmed the previous agreement on the lack of evidence 
that addition of MRI improves outcomes both in young and older women.33-35 At the present time, 
there is no clear role for routine screening by any imaging for early detection in healthy, average 
risk young women. However, in the presence of a cancer predisposition syndrome, germline 
mutation in a known cancer predisposition gene, significant family history, or prior personal history 
of ionizing radiation to the chest, consideration may be given to screening breast MRI.36, 37 Of note, 
some members of the panel considered that women harboring p53 mutations should minimize 
exposure to ionizing radiation and thus avoid mammography, and be screened by ultrasound and 
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MRI (level of evidence: Expert Opinion)38. The recommended staging, including axillary 
assessment, does not differ from that for older breast cancer patients.  
The panel strongly supported that, when MRI is used, it should be done by nationally/regionally 
approved and audited services. It also noted that the timing of the menstrual cycle should be taken 
into account when planning and performing MRI (and mammography, if done) in order to optimize 
accuracy of imaging with optimal timing being in the first half of the menstrual cycle (day 7-10) 39. 
For BRCA1/2 mutation and other cancer susceptibility genes carriers (eg RAD51C, p53) who have 
not undergone salpingo-oophorectomy, gynecologic surveillance every six months is recommended, 
beginning at age 30 or 5 years younger than the earliest diagnosis of a gynaecological malignancy 
in the family, whichever comes earlier. While these are the current recommendations, data 
supporting this approach as an effective screening method remain limited.  In addition, the best 
method to perform this gynecologic surveillance (i.e. gynecologic exam or ultrasound) is unknown. 
 
Genetic Counseling and Testing (Table 4) 
 There was discussion among the panel of whether genetic counseling should be only family 
based or considered in all breast cancer patients under 40 years. The panel concluded that genetic 
counseling should be offered for every young woman, particularly if there's a family history of 
breast cancer or the tumor is of triple negative subtype. When possible and relevant to patient care 
(e.g. selection of breast surgery), counseling should be offered before the commencement of 
treatment. The panel did emphasize that practice should be in keeping with local guidelines and 
testing availability on a country-by-country basis. For those women who are not ready to consider 
genetic issues at breast cancer diagnosis, access to genetic counseling should be offered again 
during follow-up, to address issues of specific intensive surveillance and risk reduction of additional 
primary tumors, and risk assignment and stratification for relatives. 
Genetic testing should be conducted only following genetic counseling with a genetic counselor (or 
other trained health professional) who explains the implications of the results. In addition to 
BRCA1/2 mutations, young women with breast cancer are also at risk of having rare genetic cancer 
syndromes including a germline p53 mutation (Li-Fraumeni Syndrome) or a PTEN mutation 
(Cowden’s Syndrome).40, 41 Other moderate-high-penetrance genes (e.g., CDH1, CHEK2, PALB2, 
RAD51C, BRIP1) should be tested for as deemed necessary by the geneticist. The patient must be 
made aware that the presence of a predisposing mutation may have an impact on clinical 
management, follow-up and decision making, as well as for other family members.  
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EARLY BREAST CANCER 
Loco-regional Treatment (Table 5) 
Surgery 
 Despite the fact that young age is an independent risk factor for increased local recurrence42, 
43
, a recent meta-analysis confirmed no improvement in overall survival (OS) amongst young breast 
cancer patients who underwent mastectomy compared to breast conservation44. The panel therefore 
confirmed conservative surgery as the first option whenever suitable, and expressed concern at the 
growing trend for routine mastectomies particularly in younger women. Oncoplastic repair 
techniques by a dedicated breast surgical team should be offered to all patients treated by BCS in 
order to maximize cosmetic and self-image results whenever an obvious postoperative asymmetry is 
expected. When mastectomy is indicated, skin- and nipple-sparing techniques with immediate 
breast reconstruction when feasible, can provide adequate oncological control while also addressing 
the cosmetic needs.45, 46 Immediate breast reconstruction after mastectomy offers the same survival 
rates as mastectomy without reconstruction, and should be offered to all patients except those with 
inflammatory breast cancer. With the new radiotherapy (RT) techniques there is no need to 
postpone reconstruction. 
 The panel also confirmed that the indications for SLNB and surgical management of 
patients with SLN involvement should be the same as in older patients. 
 
Radiotherapy 
 The panel reiterated BCY1 recommendations on; the need of modern techniques and high 
quality standards to minimize long-term side effects, and the routine indication for a boost to the 
site of the radical local excision. Given the high recurrence risk also outside the initial tumor area, 
partial breast irradiation is contra-indicated and should only be proposed within a clinical trial. Post-
mastectomy radiotherapy and internal mammary chain irradiation should continue to be discussed 
on an individual basis, as in older women, and based on initial staging if neoadjuvant treatment is 
given.  
 Regarding hypo-fractionated abbreviated schedules with a higher dose/fraction, a 
population-based study from Canada indicated that its use in women under 50 is growing (52% of 
women <50 years)47 with shared satisfactory safety and cosmetic outcome. With the lack of long-
term outcome data, the majority of the panel continued to agree that hypo-fractionation could be 
proposed in young patients on a case by case basis. Modern RT techniques should be used to assure 
target coverage (including nodal areas) while reducing normal tissue exposure and guarantying 
homogeneous dose delivery to avoid higher risk of fibrosis and worse cosmetic outcomes. 
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Adjuvant systemic treatment (Table 6) 
Adjuvant systemic treatment decisions for invasive breast cancer should be driven, as for women in 
other age categories, by extent of disease and the biological characteristics of the tumour (including, 
but not limiting to, hormone- and HER-2 receptors, proliferation, and grade), patient's co-
morbidities and preferences. 
Available gene expression signatures are considered to add prognostic information to classic 
clinico-pathologic factors.7, 9, 48, 49 That being said, women <40 are grossly under-represented in the 
retrospective studies performed to date. Prospective data from randomized trials (MINDACT, 
TailorX, X-PONDER, PLAN B) are awaited to assess the prognosis and benefit of chemotherapy 
according to age and tumor biology in the modern era. In the post-BCY2 preliminary report of the 
TailorX trial, young women were <5% of the total50. Thus, these tests should be used with caution 
in young women.  
Taking the above into consideration, the panel believes young age alone should not be a reason to 
prescribe more aggressive therapy but biology and stage of the tumor should always be taken into 
account when planning adjuvant treatments. 
 
Neo-adjuvant endocrine therapy (ET) 
The STAGE study evaluated neo-adjuvant endocrine therapy amongst 197 pre-menopausal patients 
by assessing clinical response, however pathologic response was not reported and the study was 
underpowered to assess long-term outcome51. An International Breast Cancer Study Group 
(IBCSG) randomized phase II Trial (IBCSG 41-13 TREND) is evaluating the efficacy of the GnRH 
antagonist degarelix versus triptorelin as neo-adjuvant treatment in 50 pre-menopausal patients 
receiving letrozole.  
 
In the absence of new data, BCY2 reinforces the BCY1 recommendation that neo-adjuvant ET 
should not be routinely recommended for young women outside of clinical trials.  
 
Adjuvant endocrine therapy  
Young women with invasive hormone receptor-positive (HR+) breast cancer should be offered 
adjuvant ET given the substantial risk reduction afforded52, 53. In the course of 2014, the long 
awaited results of the Tamoxifen and EXemestane Trial (TEXT)54 and Suppression of Ovarian 
Function Trial (SOFT)55 trials provided new insight to better individualize ET according to risk 
factors (e.g. disease characteristics, stage, adjuvant chemotherapy) and age.  
Low risk patients (e.g. older pre-menopausal patients with small, low-grade, node negative tumors) 
who do not receive adjuvant chemotherapy have excellent outcomes with 5 years of tamoxifen 
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alone (>95% 5 year Breast Cancer Free Interval (BCFI) in the SOFT trial)53, 55. Women at higher 
risk of recurrence (e.g. with node positive, larger and high-grade tumors) demanding adjuvant 
chemotherapy and remaining pre-menopausal afterwards significantly benefit from the addition of 
ovarian function suppression (OFS), by GnRH agonist (GnRHa) or oophorectomy, to tamoxifen in 
the SOFT trial, the only trial comparing a GnRHa after chemotherapy with tamoxifen in both arms 
(82.5% 5 year BCFI- in patients receiving tamoxifen plus OFS and 78.0% in patients with 
tamoxifen alone).  
Aromatase inhibitors (AIs) alone are contra-indicated in pre-menopausal women. In the TEXT and 
SOFT combined analysis OFS plus the AI exemestane significantly reduced the risk of recurrence, 
as compared with tamoxifen plus OFS and represents a new treatment option in high risk pre-
menopausal patients54, 55. The only additional evidence of AIs combined with GnRHa, provided by 
the ABCSG-12 trial in patients with favorable prognosis, the majority of whom did not receive 
adjuvant chemotherapy, did not demonstrate a difference in DFS after treatment with 3 years of 
goserelin plus either tamoxifen or anastrozole after 94.4 months median follow-up56 . Further, there 
is a long-term unfavorable trend for the anastrozole arm with respect to OS (HR=1.63; 95%CI, 
1.05-1.45; p=.030). The conflicting results between the TEXT/SOFT and ABCSG-12 trials may be 
attributable to a number of factors: different patient populations, greater statistical power of 
TEXT/SOFT and different treatment duration (5 years versus 3 years). Of note, only 18% of women 
were <40 years of age when randomized in the Austrian trial as compared to 30% and 27% in the 
SOFT and TEXT trials, respectively. Data on post-relapse treatment, body mass index (BMI) and 
long-term follow-up from the TEXT and SOFT trials will help to better interpret these differences 
and identify women most likely to benefit from OFS plus AIs. 
Very young women (<35 years) represent the subgroup who appeared to derive the greatest benefit 
from combined ET after adjuvant chemotherapy57, 58 . 
While AIs require concurrent GnRHa, the optimal duration of GnRHa plus Tamoxifen remains 
unknown: most old generation studies utilized 2-3 years of GnRH agonist with 5 years of 
tamoxifen59, 60 while in SOFT and TEXT 5 years were used 54, 55 .  
When to commence with GnRH agonist in patients receiving adjuvant chemotherapy remains a 
matter of debate. Both concomitant and sequential administrations are valuable options. In the 
TEXT combined analysis61 , the 5 years BCFI was 82.2% in SOFT patients, who received 
triptorelin a median of 8 months after the end of chemotherapy (patients could receive tamoxifen 
while waiting for ovarian function to resume), and 86% in the TEXT trial in which patients received 
triptorelin together with chemotherapy. Extended ET for premenopausal women remains 
understudied. The ATLAS and aTTom studies included premenopausal patients (10% of the overall 
population in the ATLAS trial) and provide the first and only evidence of a significant long-term 
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reduction in breast cancer mortality with 10 years of adjuvant tamoxifen as compared to 5 years, 
with an impressive carry-over benefit during the 5 years of follow-up after treatment completion62, 
63
 . BCY2 reinforces the BCY1 recommendation that extending tamoxifen beyond 5 years should be 
considered in higher-risk patients, considering the estimated absolute benefit, the risk for late 
relapse, and quality-of-life issues for the individual patient. Given the higher benefit, demonstrated 
in the MA.17 trial, of switching to the AI letrozole after 4.5-6 years of tamoxifen in women who 
were pre-menopausal at diagnosis who became definitively postmenopausal at the time of 
randomization64, consideration of AI for young women who became postmenopausal was 
confirmed in BCY2. Great caution is however recommended given the potential recovery of ovarian 
function65 . 
 
Chemotherapy may cause transient or permanent damage to the oocyte pool and ovarian reserve, 
depending on the chemotherapy regimen and cumulative dose, the pre-existing ovarian reserve, and 
the age of the woman66. Menopause occurs when the remaining follicle count reaches 1000 or 
below. While natural onset menopause is defined as twelve months after the last menstrual period, 
chemotherapy induced amenorrhoea is often mistaken for true menopause, even though menses 
may resume even after more than a year from the end of chemotherapy. As such, in the absence of a 
clear-cut definition, menopausal status following chemotherapy can be empirically diagnosed in 
case of amenorrhoea for ≥2 years , a post-menopausal hormonal profile and a vaginal ultrasound 
indicating the ovaries are no longer functioning.  
OFS is not always successfully achieved with GnRH agonists: suboptimal estrogen suppression has 
been reported in up to 1/3 of patients67, 68 . Despite the fact that estradiol assays are not standardized 
and their accuracy and interpretation can be problematic in presence of very low levels of estradiol 
69
, the panel suggests to check hormone levels if there are concerns ovarian function is not 
suppressed, especially if a breakthrough bleeding occurs and/or the patient is on an AI; if done, the 
analysis should be always performed in the same laboratory,  preferably in a central reference 
laboratory.  
Data comparing the efficacy of monthly and trimonthly formulations of GnRH agonists are lacking. 
Estradiol levels did not differ significantly between monthly goserelin and trimonthly leuprolide in 
79 early breast cancer patients receiving GnRH agonists for at least 6 months70 but further research 
is needed before trimonthly administration can be routinely recommended in women <40 years of 
age.  
 
Younger age is associated with low adherence and persistence to adjuvant ET71, 72 . The mean 
adherence to adjuvant AIs in postmenopausal women is also known to decrease over time73 . In 
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SOFT, tamoxifen was discontinued early in 16.7% of the tamoxifen–OFS group and non-adherence 
with OFS reached 21.9% at 4 years55. In TEXT, 16.1% of the patients in the exemestane–OFS 
group stopped all protocol assigned treatments early54. Healthcare professionals should therefore 
encourage young patients to persist with the assigned ET or discuss all toxicity issues and ways to 
overcome them, as well as any possible treatment modification. 
 
Many of the side effects of adjuvant ET mimic menopause and may significantly impact quality of 
life (QoL). The self-reported QoL showed increased menopausal symptoms and decreased sexual 
activity of OFS over tamoxifen alone in the E-3193 trial74 and of exemestane over tamoxifen in the 
TEXT trial, but symptoms diminished over time and the overall QoL was not significantly different 
between treatment arms75 . Healthcare providers should follow young patients on ET closely in 
order to promptly manage side effects or discuss treatment adjustments according to individual 
tolerance which may require a change of therapy. .  
The inconvenience, cost, and availability of the different treatment options must also be considered 
when tailoring ET for the individual patient. 
 
GnRH agonists & Ovarian function preservation 
The effectiveness of GnRH agonists to preserve ovarian function in women receiving 
chemotherapy, thus reducing the risk of early menopause and increasing the chances for future 
fertility, has not yet been fully elucidated. Despite limitations in study design and statistical power, 
the most recent randomized controlled trials suggest a protective ovarian effect in both HR+ and 
HR- patients and no signal for harm from a breast cancer recurrence standpoint76, 77 . A recent meta-
analysis supports these findings78. The BCY2 panel therefore agreed this strategy can be discussed 
with patients interested in potentially preserving fertility and/or ovarian function.  
 
Adjuvant Bisphosphonates 
After BCY2 the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis was 
published which confirmed the lack of benefit of adjuvant bisphosphonates among premenopausal 
women79. The BCY2 panel, in keeping with the recommendation of BCY1, agreed that 
bisphosphonates should not be considered standard adjuvant therapy for premenopausal women at 
this time, although can be used for prevention of loss of bone density.80-82   
 
Neo/adjuvant chemotherapy 
 The additional benefit, if any, of adjuvant chemotherapy in young patients with low risk 
HR+ early breast cancer under optimal endocrine therapy is still undetermined. All prospective 
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randomized trials have failed in recruiting enough patients to definitively answer this question83, 84 . 
To overcome the scarcity of randomized data, a growing bulk of indirect evidence seems to suggest 
that young women with low-risk HR+ early breast cancer could be spared chemotherapy. The phase 
III Eastern Cooperative Oncology Group trial (E-3193, INT-0142) in premenopausal patients with 
node-negative HR+ early breast cancer74 , showed a greater than 95% 10 year OS in the absence of 
chemotherapy; in the SOFT and TEXT patients who did not receive chemotherapy (8% and 21% 
node-positive, respectively) the 5 year BCFI was 96% and 97%, respectively with similar favorable 
outcomes in the ABCSG trial54, 56, 85. 
 The panel restated that there is no evidence to recommend a specific chemotherapy regimen 
for young women requiring neo/adjuvant chemotherapy. In the last EBCTCG meta-analyses 
involving taxane- or anthracycline-based regimens, proportional risk reductions were little affected 
by age.86 Sequential regimens have at least equal or superior efficacy over combination regimens 
and may be better tolerated although this has not been evaluated specifically in young women87. A 
sequential regimen of anthracycline based chemotherapy followed by adequately dosed CMF (oral 
or Day1,8 every 21 days intravenously) or a combination of a taxane and cyclophosphamide may be 
valid alternatives88, 89. Similar to older women, standard duration of treatment should include 
between 4 to 8 cycles of treatment  
 Although higher local relapse rates after neo-adjuvant chemotherapy and breast conservation 
have been seen in young women, no long-term significant survival harm from neo-adjuvant 
chemotherapy and subsequent conservative surgery in young women has been demonstrated.90 A 
pooled analysis of individual patient data from eight prospectively randomized controlled trials of 
the German Breast Group, published after BCY2, showed that young women (n=1453) are more 
likely to achieve pCR after neoadjuvant chemotherapy, especially in HR+/HER2- and triple 
negative disease (20.9 vs. 17.7 vs. 13.7%; p<0.001). Age was not prognostic in triple negative and 
HR-/HER2+ patients as opposed to HR+/HER2- disease103. The Geparsixto trial & CALGB trials 
demonstrated improved pCR amongst triple negative disease with the incorporation of platinum 
agents. No long term survival data is available therefore platinum agents while may be considered 
should not be routinely incorporated into neo-adjuvant regimens until further data is available91, 92.  
 
Adjuvant anti-HER-2 therapy 
 There is still no evidence to recommend a specific HER2-targeted regimen and treatment 
duration for young women with HER-2+ early breast cancer: the benefit of adjuvant trastuzumab 
appears independent of age in all published studies.  9  
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Side effects of adjuvant therapy 
 In view of the longer life expectancy of young women, the panel reinforced the need to 
monitor potential long-term toxicities (i.e. cardiovascular, bone morbidity, cognitive impairment). 
Further, young women have been documented to be at greater risk of psychosocial morbidity after a 
diagnosis of breast cancer, particularly those who receive chemotherapy and undergo a menopausal 
transition with treatment93, 94. 
 
Inflammatory Breast cancer  
Inflammatory breast cancer should be managed the same as for the older breast cancer population.  
 
Advanced Breast Cancer (ABC) (Table 7) 
 There are few proven standards of care in ABC management overall and even more so in 
young women. Thus, the development of well-designed, independent, prospective randomized trials 
in ABC was stressed in BCY2, with efforts to augment inclusion of young patients.23   
 Further, as is the recommendation for early breast cancer, young age alone should not be a 
reason to prescribe more aggressive therapy, and international consensus guidelines for 
management of ABC should be applied52, 95. 
 The BCY2 panel endorses the ESO-ESMO ABC 2 guidelines for the management of 
Luminal ABC in pre-menopausal women. 
 BCY2 recommendations reiterated that treatment strategies should not differ from those for 
older women with the same disease characteristics and young age by itself is not an indication to 
prescribe combination chemotherapy over sequential use of monotherapy. The unique medical and 
psychosocial concerns of young women should be addressed and individualized when caring for 
young women in the metastatic disease setting.  
 
Loco-regional relapse 
Young age is a risk factor for local relapse. The recommendations for young women do not 
differ from those for the general patient population although particular attention to margin status 
may be warranted in young women. In keeping with practice for older women, chemotherapy after 
loco-regional therapy should be considered, particularly in women with HR-negative tumors, based 
on evidence for benefit in DFS and OS seen in the CALOR trial96. 
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BRCA mutation carriers (Table 8) 
 The indications and modalities of MRI surveillance in high-risk patients still refer to the 
2010 EUSOMA guidelines which considered different imaging modalities in the surveillance of 
high-risk women.36 
 The BCY2 panel confirmed BCY1 recommendations for prevention, surveillance, treatment 
and risk reducing strategies. In particular (i) there is still no definitive evidence that therapeutic 
mastectomy plus contralateral risk-reducing mastectomy has an impact on survival in a woman with 
early breast cancer in the context of a hereditary cancer syndrome and, (ii) breast imaging is a 
screening/surveillance tool for detecting early disease whereas surgery is a risk-reducing procedure 
for actively reducing the risk of the development of disease 97-99   
 The availability of rapid BRCA testing would favorably impact on the treatment plan but 
adequate time should be given to the patient to allow the proper understanding of all genetic based 
information and its consequences to avoid “rush decisions”. 
 Regarding bilateral risk-reducing salpingo-oophorectomy (RRSO) for the prevention of 
ovarian cancer amongst women harboring a BRCA1/2 mutation, the panel members recommended 
this be performed between ages 35-40 (no consensus on the exact age), as recommended by NCCN 
and NICE guidelines100, 101,  taking into consideration the specific family history and provided the 
woman has completed childbearing.102, 103. In women not considering RRSO, gynecologic 
surveillance every six months is still recommended: the panel did not endorse routine CA-125 
testing, or transvaginal ultrasound, in agreement with several available guidelines.104. While recent 
data in mutation carriers further support the evidence that the use of oral contraceptives is 
associated with a significant reduced risk of ovarian cancer for BRCA1/2 carriers with no clinically 
significant increased breast cancer risk with recent formulations,105-107 the safety of this strategy in 
breast cancer survivors has not been tested. For women who choose not to undergo risk reducing 
contralateral mastectomy, RRSO at young age reduces risk of new breast primaries. 
 Still, there is no definitive conclusion on the best chemotherapy regimen for BRCA-
associated breast cancer patients and the panel recommended that standard prognostic features 
should be used to decide treatment in the early disease setting.108 Based on the results of the 
Geoparsixto trial (see above), the use of platinum may be considered in BRCA-associated triple 
negative breast cancer92 Following the results of the TNT study, the use of a platinum agent should 
be considered in the advanced breast cancer setting of BRCA-associated ABC109. 
 Poly (ADP-ribose) polymerase (PARP) inhibitors are being developed as therapeutic agents 
for germline and somatic BRCA-mutated breast cancer patients, both in the early and advanced 
settings.110, 111. 
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Supportive and follow-up care (Table 9) 
 In principle, follow-up care in young women should follow the same guidelines as in older 
women.112  Supportive treatment of specific symptoms/side effects should also follow current 
recommendations as for older women. 
 In many settings, breast nurses are of crucial importance to address and support the unique 
psychosocial and sexual issues of young patient and their families. The panel reinforced the need to 
address social issues (e.g. return to work, family planning, financial loss) and feelings of 
inadequacy (e.g. fear of starting a new relationship, partner’s strain). 
 
Some of the specific issues for the young breast cancer population include: 
Fertility, Contraception and Premature Menopause: Fertility and family planning are major 
concerns for young women with breast cancer.14, 113 Many young women will still be fertile after 
treatment and some will be interested in having a future biologic child.  Discussion of these issues 
at diagnosis, elicitation of patient interest in future fertility and appraising patients of the risks of 
amenorrhea and potential infertility as well as premature menopause have been recommended by 
other guideline panels as an important component of quality oncology care114 and are reinforced 
here.114 Appropriate early referrals for fertility preservation strategies, based on existing practice 
guidelines,114 as well as psychosocial support surrounding this extremely complex issue should also 
be made. There was recognition by the majority of the panel that this is one of the most difficult and 
emotionally challenging issues facing young survivors, which is complicated by limitations of the 
data, particularly with regards to predicting fertility as well as safety of intervention. Pregnancy is 
prohibited due to risk of teratogenesis during active treatment of breast cancer so effective 
contraception is recommended and proactive counseling should be done on this issue for each 
patient. Exogenous hormonal contraception is generally contraindicated in breast cancer survivors 
and alternative strategies (i.e. barrier methods such as condoms, cervical diaphragm and copper 
IUDs, or male contraception) should be considered.115 The safety of levonorgestrel-releasing intra-
uterine device (IUD) (Mirena®), which delivers high local but low systemic doses of progestogen is 
controversial: studies in BC survivors are small and have not included recurrence or new cancers as 
an endpoint.116 In the absence of prospective data patients should be advised to use alternative non-
hormonal contraception.  
Premature menopausal symptoms may include vasomotor symptoms, sleep disturbance, fatigue and 
weight gain as well as sexual dysfunction – all of which can be very distressing for young 
women117. For hot flashes studies of megesterol acetate and medroxyprogesterone acetate have been 
performed and appeared efficacious118-120, however long term safety data is limited. Numerous 
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studies exist that evaluated the use of non-hormonal medications and acupuncture in the 
management of hot flashes but this is beyond the scope of these guidelines. 
 
 
Sexual functioning: sexual dysfunction is a major issue having significant impact on quality of life 
both amongst women with chemotherapy-induced amenorrhea121 and amongst women receiving 
OFS and oral ET55, 61. This issue encompasses vaginal dryness, dyspareunia, decreased libido, body 
image concerns, anxiety and depression, fatigue and side-effects from medications (including anti-
depressants). Appropriate counseling should be available and vaginal moisturizers and lubricants 
should be prescribed122. Sexual health should be included in the survivorship care plan and further 
research is needed to improve management of these123. In patients where aforementioned measures 
do not help consideration of limited and selective use of hormonal agents with a conversation about 
the lack of data on risk may be considered. This may include vaginal estrogens which may be safer 
in those on tamoxifen than AI, however safety data is limited.  
 
Pregnancy after breast cancer: all retrospective available data report no detrimental effect of a 
subsequent pregnancy on breast cancer outcome.124-129 In particular, in a recent multicenter, 
retrospective cohort study in which 333 patients who became pregnant any time after BC were 
matched (1:3) to patients with BC with similar ER status, nodal status, adjuvant therapy, age, and 
year of diagnosis, no difference in DFS was observed between pregnant and non-pregnant patients 
in the HR+ population at a median follow-up of 5 years following conception.126  Therefore, 
pregnancy after breast cancer should not be discouraged, even though definitive data from 
prospective clinical trials are needed.127 A prospective global cooperative study, the POSITIVE 
study has been commenced with the aim of assessing the safety and feasibility of interrupting ET 
for pregnancy after breast cancer – enrolment in the study should be strongly encouraged among 
women who desire early pregnancy after diagnosis, as this will likely be the only prospective study 
on pregnancy after breast cancer. 
 
Bone health: bone health should be checked regularly (similar to older women) in young women 
with breast cancer, especially in those receiving OFS plus oral ET. Of note, in contrast with its 
effects on bones in post-menopausal women, tamoxifen can cause bone loss in premenopausal 
patients, likely because it is a weaker agonist in the bones that the premenopausal endogenous 
estrogens it is blocking.130, 131  As a consequence, in all young patients special emphasis on dietary 
education [i.e. adequate intake of calcium through diet and supplements (1000 mg/day) and vitamin 
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D (800-1000 UI/day)] and regular weight-bearing exercise is needed.132 Treatment-related bone loss 
should be managed accordingly, independent of age. 
 
Cognitive impairment: Neurocognitive symptoms (“onco or chemo brain”) are frequently 
described among young breast cancer survivors.133, 134  Patient-reported symptoms (forgetfulness, 
difficulty with concentration, fatigue, distractibility and difficulty with word finding) rarely 
correlate with neuro-imaging studies and neuro-psychiatric evaluation. Neither the biological basis 
for this syndrome, nor the predictors, nor any interventions, are well understood although recent 
investigations suggest a relationship with structural changes occurring in cerebral white matter and 
several investigations are underway.135, 136  While much of the prior work has focused on the effects 
of chemotherapy, ET may also adversely affect cognition,137-140 although few specific investigations 
have been conducted and none in young women. In the ZIPP trial (6 cycles of CMF ± 2 years of 
goserelin, goserelin plus tamoxifen, or tamoxifen), no effect of treatment on patients’ self-
evaluation of memory and concentration was shown.141  Cognitive function is being prospectively 
investigated in patients participating in the SOFT trial. 
 
Lifestyle changes: The panel endorsed that young patients should be strongly encouraged to adopt 
healthy lifestyle changes that include maintaining healthy BMI (≤25), performing regular aerobic 
exercise (equivalent of at least 150 minutes/week of at least moderate intensity)142, not smoking and 
limiting alcohol intake.  
 
Breast cancer during pregnancy: management of patients with breast cancer during pregnancy is 
outside of scope of these guidelines and should follow established recommendations143.  In general 
pregnant women can and should be treated as closely as possible to the general guidelines for 
BCYW. Patients should be enrolled in prospective registration studies144. 
 
Conclusions 
 Loco-regional and systemic treatment of breast cancer in young women should not 
substantially differ from women in other age groups as management is guided by the stage and 
biology of the tumor, both in the early and advanced disease setting. However, care of young 
women must emphasize and address the unique issues specific to their age and life situation – 
ranging from fertility and pregnancy-related issues, long-term toxicities of treatment and 
psychosocial problems including long-term quality of life and cosmetic outcomes. All efforts 
should be made globally by the research community (academia, pharmaceutical industries, 
independent funding sources, advocacy groups) to develop research programs addressing the 
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unanswered questions regarding the optimal management of breast cancer in young women, in 
order to overcome the lack of statistical power in smaller studies and possible conventional 
prejudices of the medical community. Additionally, prospectively planned subgroup analyses in 
additional trials across age groups may add important knowledge and thus help to improve 
management in young women.  
 In routine clinical practice, the culture of multidisciplinary management and care is strongly 
recommended to avoid a dogmatic standard of practice and the risk of overtreatment, in particular, 
in young women. The role of patient advocacy for this age group is also crucial, particularly for 
dissemination of information and knowledge. 
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Table 1: Levels of evidence grading system22  
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Table 2: General Recommendations 
Guideline statement LoE 
1. Many specific issues in the treatment of young women with BC, both in the early and in the advanced settings, still lack 
definitive proven standards. Therefore, well-designed, independent, prospective randomized trials should be a global 
research priority 
Expert Opinion 
2. The care of all young patients with breast cancer (either early stage, EBC, or advanced disease, ABC) should be 
discussed within a multidisciplinary team before any treatment decision-making, and provided in specialized breast 
clinics.  
Expert Opinion 
3. Navigators/navigation tools are of great assistance in optimizing patient care. Navigators should ideally be breast nurses 
but lay-health professionals with strong communication skills and sufficient experience may also address complex care 
and mixed cultural settings. 
Expert Opinion 
4. In view of the many specific aspects related to young age, personalized psychosocial support, counseling on genetic 
predisposition, fertility, sexual health, & socio-economic impact are highly recommended as part of the individual 
treatment planning. 
Expert Opinion 
5. Young age by itself should not be the reason to prescribe more aggressive therapy than other age groups. Factors 
influence choice of treatment should include but not be limited to the complete biological characteristics of the tumor 
(ER/PR, HER-2, proliferation markers (e.g. Ki-67), histological grade), tumor stage, hormonal milieu, genetic status (if 
available) and patient’s co-morbidities and preferences. 
Expert Opinion 
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Table 3: Screening, Diagnosis & imaging for Staging and Follow-up 
Guideline statement LoE 
6. There is no clear role for routine screening by any imaging for early detection in healthy, average risk young women. 
However, in the presence of a cancer predisposition syndrome, germline mutation in a known cancer predisposition 
gene, significant family history, or prior personal history of ionizing radiation to the chest, consideration may be given to 
screening breast MRI. 
IA 
Expert Opinion 
7. Diagnosis, imaging and staging in young women should follow standard algorithms consistent with older women.  
 Additional consideration may be given to ultrasound and breast MRI in young women particular in the setting of       
very dense breast tissue or consideration of a genetic predisposition or other high risk individuals (i.e. radiotherapy for 
childhood malignancy). 
2C 
8.  For BRCA 1/2 mutation carriers and others at extremely high risk based on family history or predisposing 
mutations in other genes, and for those at increased risk because of a personal history of therapeutic radiation, 
annual surveillance with mammography and MRI with or without ultrasound is recommended. 
IC 
9. For BRCA 1/2 mutation and other cancer susceptibility genes carriers (eg RAD51C, p53) who have not undergone 
salpingo-oophorectomy, gynecologic surveillance every six months is recommended, beginning at age 30 or 5 years 
younger than the earliest diagnosis of a gynaecological malignancy in the family, whichever comes earlier. 
Expert Opinion 
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Table 4: Genetic Counseling and Testing 
Guideline statement LoE 
8. Every young woman with breast cancer should be offered genetic counseling preferably before starting the treatment. 
Practice should be consistent with local-guidelines on a country-by-country basis. For those women who are not ready to 
consider genetic issues at breast cancer diagnosis, access to genetic counseling should be offered again during follow-up, 
to address issues of surveillance and risk reduction of additional primary tumors for the patient, and risk issues for 
relatives. 
 Expert Opinion 
9. Genetic testing should be conducted only following genetic counseling with a genetic counselor (or other trained health 
professional) who explains the implications of the results. The patient must be made aware that the presence of a 
predisposing mutation may have an impact on her management, follow-up and decision making, as well as family 
members. Genes to be tested for are BRCA1 and BRCA2 (other additional high-penetrance genes can be tested if 
deemed necessary by the geneticist)  
Expert Opinion 
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Table 5: Early Breast Cancer Loco-regional Treatment  
Guideline statement LoE 
10. Surgical treatment of young patients with EBC – while being tailored to the individual patient - should in general not 
differ from that of older patients.  
Breast conserving surgery should be performed as the first option whenever suitable, as it provides the same OS than 
mastectomy.  
I B 
 
I A 
11. Oncoplastic repair techniques should be offered to all patients treated by BCS in order to maximize cosmetic and self 
image results whenever an obvious postoperative asymmetry can be estimated by dedicated breast surgical team. 
Immediate breast reconstruction after mastectomy offers the same survival rates as mastectomy without reconstruction 
and should be offered to all patients except those with inflammatory breast cancer.  
I C 
12. There is no evidence of an increased false negative rate or a worse outcome in young patients undergoing SNLB, 
therefore the indications for SNLB are the same as in older patients. 
I B 
13. In young women with the diagnosis of either invasive disease or pre-invasive lesions, who are not BRCA mutation 
carriers, there is no evidence for improved OS by performing risk-reducing bilateral mastectomy. 
IC 
14. For all surgical decisions and particularly for risk-reducing mastectomy, patients must be given proper, thorough and 
unbiased information based on the available data, and adequate time to decide, since breast surgery is not an emergency. 
Once an informed decision is taken by the patient it should be respected. Additional psychosocial support should be 
offered given the potentially high anxiety and long term sequela of patients making these difficult decisions. 
Expert Opinion 
15. Indications for adjuvant RT are the same as for older patients. Data are more robust in support of the benefits of post-
mastectomy (PM) RT and internal mammary chain RT for young women. 
I B 
16. After breast-conserving surgery, breast radiation + boost is recommended. Young patients should be informed about the 
high local recurrence risk if RT is avoided after BCS and about the benefit of RT on reduction of local recurrence and 
IB 
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improvement in OS. This must be balanced with information about the potential long-term toxicities.  
17. Hypofractionation can be discussed in selected cases 2B 
18. Indications of adjuvant RT are independent of BRCA status Expert Opinion 
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Table 6: Adjuvant Systemic Treatment 
Guideline statement LoE 
19. All young women should be counselled about the risks, associated symptoms and outcomes of treatment-related  
amenorrhea and premature menopause before the onset of systemic therapy (either CT or ET) and referred for special 
counselling/consultation. 
Expert Opinion 
20.  Neoadjuvant ET should not be used in young women outside clinical trials. Expert opinion 
21. All patients with HR positive disease should receive adjuvant ET.  
Tamoxifen alone for 5 years is indicated for low risk patients.  
Switching to an AI, after 5 years of tamoxifen, should be considered for women who have become definitively post-
menopausal. 
    Tamoxifen for 10 years should be considered in high-risk patients, if tolerated. 
    The addition of a GnRH agonist to tamoxifen is indicated in patients at higher risk who remain premenopausal after       
chemotherapy.  
IA 
IA 
IA 
 
IA 
IA 
22. AIs alone are contra-indicated in pre-menopausal women.  
The combination of an aromatase inhibitor and a GnRH agonist (or ovarian ablation) should be considered in high risk 
patients if tolerated. 
IA 
IA 
23. Young women with stage I or II breast cancer who cannot take tamoxifen (due to contraindications or severe side 
effects) may receive a GnRH agonist alone, oophorectomy or an aromatase inhibitor + GnRH agonist. The optimal duration 
of GnRH agonist alone is currently unknown. The choice will depend on risk of relapse, toxicity and patient preferences. 
IA  
24. If a GnRH agonist is used in this age group, it should be given on a monthly basis (and not on a 3-monthly basis) to 
optimize ovarian suppression. 
Estradiol levels should be checked if there are concerns ovarian function is not suppressed, especially if a breakthrough 
2 B 
 
Expert Opinion 
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bleeding occurs and/or the patient is on an AI; if done, the analysis should be always performed in the same laboratory, and 
preferably in a central reference laboratory. . In cases of inadequate suppression alternative strategies should be discussed 
(oophorectomy or continuation of tamoxifen alone). 
25. Young patients (>35 years at diagnosis) with low risk HR positive disease have excellent outcomes with ET alone: the 
addition of adjuvant chemotherapy should not be standard but discussed on an individual basis.  
IB 
26. The indications for and the choice of adjuvant systemic treatment for invasive breast cancer should be driven, as for 
women in other age categories, by extent of disease and the biological characteristics of the tumour (including, but not 
limiting to, ER/PR and HER-2 receptors, proliferation, and grade), patient's comorbidities. 
LoE IA  
27. For the time being, the type of systemic treatment of EBC is independent of BRCA or any other constitutional genetic 
status.  
Expert Opinion 
28. The optimal (neo)adjuvant CT regimen specifically for young women regarding efficacy and long-term tolerance is 
currently unknown. As for all stage I-III breast cancer patients, the preferred regimens are standard anthracycline, 
alkylating, and taxane based regimens.  
IA 
 
 
29. Standard duration of treatment (minimum of 4 and maximum of 8 cycles) should be prescribed.  
 Sequential regimens have at least equal or superior efficacy over combinations and are better tolerated. 
Young age by itself should not be an indication to prescribe a combination of cytotoxic agents.  
IA 
IA 
30. One year treatment with adjuvant trastuzumab, together with chemotherapy, is indicated for women with HER-2-
positive, node-positive or high-risk node-negative breast cancer (tumor size > 0.5 cm), having a left ventricular ejection 
fraction of ≥55% and without important cardiovascular risk factors, regardless of age. 
I A 
 
31. In view of the long potential life expectancy, particular attention should be paid to possible long-term toxicities of 
adjuvant treatments (e.g. secondary cancers, cardiovascular toxicity, irreversible ovarian failure, weight gain, cognitive 
function, bone health). 
Expert Opinion 
28 
 
32. The management of inflammatory breast cancer in young women should be the same as in the older breast cancer 
population. 
Expert Opinion 
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Table 7: Advanced Breast Cancer 
Guideline statement LoE 
33. Also in the metastatic setting, age alone is not a reason to prescribe more aggressive therapy and International 
Consensus Guidelines for management of advanced breast cancer must be applied (ABC 2, ESMO and NCCN 
guidelines).  
     Therapeutic recommendations should not differ from those for older women with the same disease characteristics and 
extent. 
Expert Opinion 
 
 
IC 
34.The BCY2 panel endorses the ESO-ESMO ABC 2 guidelines for the management of Luminal ABC in pre-menopausal 
women. 
IA 
35. Well designed prospective randomised trials evaluating the role of platinum agents in the population of BRCA 1/2 
mutation associated ABC are urgently needed.  
      For now, in women who BOTH harbour a BRCA mutation AND have "triple negative" subtype use of platinum agents 
may be considered in the advanced disease setting.  
Expert Opinion 
 
IB 
36. Although young age has been associated with an increased risk of CNS metastases, surveillance and therapeutic 
recommendations should not differ from those for older women with the same disease characteristics and extent, since 
clinical and pathologic characteristics predicting for CNS recurrence often overlap with factors that indicate increased 
risk for general metastatic dissemination (i.e. young age, ER- and PR-negativity, HER-2 overexpression, high 
I C 
30 
 
proliferation, and genomic instability). 
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Table 8: Germline BRCA 1/2 mutation carriers  
37.  For survivors harboring a BRCA 1/2 or (other) strongly predisposing mutation, bilateral risk-reducing mastectomy may 
be considered, although there is no definite evidence that it leads to a survival benefit. Therapeutic decisions should 
reflect a balance between the risk of recurrence of the diagnosed breast cancer and the potential benefit of preventing an 
additional primary tumor 
IIB 
 
 
38. For survivors harboring a BRCA 1/2 mutation, risk-reducing salpingo – oophorectomy should be discussed from the age 
of 35 provided that the woman has completed family planning, and should preferably be done before 40, always 
respecting patient’s preferences and considering the family history. 
I B 
39. For the time being, the radiotherapy treatment of EBC is independent of BRCA or any other constitutional genetic 
status, with the exception of germline TP53 mutations, for which a very high risk of secondary cancers has been 
described after radiation therapy. Radiation therapy should be carefully discussed in an individual basis for these 
patients. 
I B 
 
III 
40. The same guiding principles defining treatment decisions should be applied for all women with ABC regardless of 
genetic status. Systemic therapy recommendation for BRCA-associated early BC are the same as for the non-BRCA-
associated, with the exception of possible consideration of platinum in the neo-adjuvant setting of BRCA-associated 
triple negative BC. 
I B 
 
IIB(for platinum) 
 
41. A platinum agent should be considered in the treatment of BRCA-associated advanced breast cancer.  IB 
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Table 9: Supportive and follow-up care 
Guideline statement LoE 
42. Young women with breast cancer face specific physical, psychosocial and sexual issues that should be addressed by a 
multidisciplinary group of providers including breast medical, surgical and radiation oncologists, breast nurses, social 
workers, psycho-oncologists, gynecologists and fertility experts, among others.  
Expert Opinion 
43.  All young women should be counselled regarding the risk of getting pregnant while on chemotherapy, endocrine or 
anti-HER-2 therapy, despite developing amenorrhea, and of the need for adequate non-hormonal contraception if they 
are sexually active and could become pregnant. 
Exogenous hormonal contraception is generally contraindicated in young cancer survivors, irrespective of disease 
subtype, and alternative strategies should be considered. 
I B 
 
 
Expert Opinion 
 
44. All young women should be referred for special counseling/consultation if interested in fertility preservation prior to   
commencement of any therapy.  
45. The use of GnRH analog concomitant with adjuvant CT should be discussed on a case by case basis to preserve ovarian 
function and possibly fertility  
Expert Opinion 
 
I C 
46. All young women should be counselled about the risks and associated symptoms and outcomes and management of 
treatment-related amenorrhea and premature menopause before the onset of systemic therapy (either CT or ET) and 
informed of available ameliorative therapies. 
Expert Opinion 
47. Premature menopause and/or treatment related amenorrhea increase the risk of bone thinning and patients should be 
counselled, monitored and treated accordingly. 
I A 
48. Pregnancy after breast cancer should not be discouraged even in patients with HR positive disease, although all data 
available have limitations. 
 
I B 
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49. Treatment of patients with breast cancer during pregnancy should be decided on an individual basis according to 
international guidelines within an expert multidisciplinary team, expanded to include obstetricians and perinatologists, 
and according to patients’ preferences.  
Expert Opinion 
50. Young patients should be strongly encouraged to adopt the following healthy life style changes: 
• maintain BMI ≤ 25 
• perform regular aerobic exercise 
• not to smoke 
• to limit daily alcohol intake 
Expert Opinion 
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